Your browser is no longer supported. Please, upgrade your browser.
Settings
SRNE Sorrento Therapeutics, Inc. daily Stock Chart
SRNE [NASD]
Sorrento Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.57 Insider Own1.80% Shs Outstand127.22M Perf Week-22.41%
Market Cap418.55M Forward P/E- EPS next Y-0.68 Insider Trans-11.50% Shs Float79.97M Perf Month-10.60%
Income-61.00M PEG- EPS next Q-0.19 Inst Own26.40% Short Float23.12% Perf Quarter-37.92%
Sales152.50M P/S2.74 EPS this Y109.70% Inst Trans2.71% Short Ratio11.53 Perf Half Y-54.31%
Book/sh2.53 P/B1.30 EPS next Y- ROA-13.60% Target Price21.67 Perf Year43.04%
Cash/sh0.37 P/C8.89 EPS next 5Y37.00% ROE-30.60% 52W Range2.15 - 10.65 Perf YTD-13.42%
Dividend- P/FCF- EPS past 5Y17.90% ROI27.40% 52W High-69.11% Beta2.66
Dividend %- Quick Ratio1.40 Sales past 5Y204.10% Gross Margin97.00% 52W Low53.02% ATR0.37
Employees162 Current Ratio1.40 Sales Q/Q-17.00% Oper. Margin-2.10% RSI (14)43.69 Volatility11.40% 10.86%
OptionableYes Debt/Eq0.07 EPS Q/Q-264.00% Profit Margin-39.40% Rel Volume1.09 Prev Close3.56
ShortableYes LT Debt/Eq0.06 EarningsNov 15 Payout- Avg Volume1.60M Price3.29
Recom1.70 SMA20-4.87% SMA50-17.64% SMA200-45.71% Volume1,886,867 Change-7.58%
Jun-28-18Initiated B. Riley FBR, Inc. Buy $14.25
Jan-16-18Reiterated H.C. Wainwright Buy $20 → $30
May-22-17Reiterated Rodman & Renshaw Buy $30 → $20
May-22-17Reiterated FBR & Co. Outperform $13 → $9
Oct-03-16Initiated ROTH Capital Buy
Apr-06-16Reiterated FBR Capital Outperform $21 → $16
Mar-16-16Reiterated FBR Capital Outperform $22 → $21
Dec-22-15Initiated FBR Capital Outperform $22
Dec-07-15Resumed Rodman & Renshaw Buy $45
Aug-03-15Resumed MLV & Co Buy $34
Jul-29-15Reiterated Brean Capital Buy $17 → $26
May-28-15Initiated Brean Capital Buy $17
Mar-17-15Reiterated H.C. Wainwright Buy $13 → $20
Oct-02-14Initiated H.C. Wainwright Buy $11
Jun-19-14Initiated MLV & Co Buy $9
Dec-03-13Initiated Aegis Capital Buy $40
Nov-21-13Initiated CRT Capital Buy $11
Nov-08-18 07:00AM  Sorrento Therapeutics Closes Five-Year Term Loan Financing for Up to $150 Million GlobeNewswire -5.66%
Nov-06-18 08:01AM  Sorrento Therapeutics Anti-CEA CAR-T Demonstrates Significant Therapeutic Activity With Increased Overall Survival in Pancreatic Cancer Patients With Liver Metastases GlobeNewswire
Nov-01-18 07:00AM  Sorrento Therapeutics Announces the Initiation of Dosing in Its Anti-CD38 CAR-T Phase 1 Clinical Study for Relapsed or Refractory Multiple Myeloma GlobeNewswire +12.85%
Oct-25-18 08:10AM  Research Report Identifies Sorrento Therapeutics, Hurco Companies, Veritiv, Park Electrochemical, VBI Vaccines, and PennantPark Floating Rate Capital with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire +7.89%
Oct-11-18 05:04PM  Here's Why Sorrento Therapeutics Fell 20.7% in September Motley Fool
Oct-05-18 02:16PM  10 Growth Stocks to Buy With Monster Potential Kiplinger
Oct-01-18 08:00AM  Scilex Announces the Availability of ZTlido GlobeNewswire -6.14%
Sep-27-18 06:09PM  Sorrento Therapeutics to Present at the Leerink Partners Roundtable Series 10/3/2018 GlobeNewswire
Sep-19-18 08:00AM  Scilex Announces Pricing and Availability of ZTlido for the Commercial Launch of its First Product in October of 2018 GlobeNewswire
Sep-10-18 04:00AM  Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing to Support the Commercialization of Non-Opioid ZTlido Pain Medication GlobeNewswire +11.11%
Sep-07-18 12:24PM  Scilex Presents ZTlido Data on Superior Adhesion over Lidocaine Patch Formulation PR Newswire
Sep-04-18 08:30AM  Research Report Identifies Brady, Akari Therapeutics, MTGE Investment, Jones Lang LaSalle, New Relic, and Sorrento Therapeutics with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Sep-02-18 01:19PM  Sorrento Therapeutics to Present at FB Riley and HC Wainwright Sept 2018 Healthcare Conferences in NYC (NY) GlobeNewswire
Aug-13-18 09:42AM  Sorrento's Knee Pain Medication Found Safe, Effective Based On Early Data Benzinga
04:00AM  1st Patient Treated for Osteoarthritis Knee Pain in Sorrento Resiniferatoxin Phase 1B Trial Meets Both Safety and Efficacy Expectations GlobeNewswire
Jul-23-18 08:10AM  Todays Research Reports on Stocks to Watch: Ampio Pharmaceuticals and Sorrento Therapeutics ACCESSWIRE
07:05AM  Complimentary Technical Snapshots on Sorrento Therapeutics and Three More Biotech Stocks ACCESSWIRE
Jul-05-18 05:32PM  Why Clean Energy Fuels, Sorrento Therapeutics, and iQiyi Slumped Today Motley Fool -7.75%
04:11PM  Why Sorrento Therapeutics, Inc. Stock Sank Today Motley Fool
Jul-03-18 09:30AM  Sorrento Acquires the Sofusa Lymphatic Delivery Platform for Immune-Oncology (I-O) Antibody Therapeutics GlobeNewswire
Jun-26-18 07:15AM  Complimentary Technical Snapshots on Sorrento Therapeutics and Three More Biotech Stocks ACCESSWIRE +11.81%
Jun-14-18 04:42PM  Sorrento Therapeutics issues Chairman/CEO corporate update to stockholders GlobeNewswire
10:31AM  Hong Kong market could open cash flood gates for U.S. biotechs Reuters
10:18AM  Hong Kong market could open cash flood gates for U.S. biotechs Reuters
May-25-18 07:10AM  Free Research Reports on Sorrento Therapeutics and Three More Biotech Stocks ACCESSWIRE
May-24-18 07:47PM  An Intrinsic Calculation For Sorrento Therapeutics Inc (NASDAQ:SRNE) Shows Its 26% Undervalued Simply Wall St. +5.30%
May-11-18 08:30AM  Consolidated Research: 2018 Summary Expectations for Sunstone Hotel Investors, Plains All American Pipeline, Sorrento Therapeutics, TD Ameritrade Holding, Meritor, and DXC Technology Fundamental Analysis, Key Performance Indications GlobeNewswire
May-08-18 08:30AM  Today's Research Reports on Trending Tickers: Sorrento Therapeutics and Illumina ACCESSWIRE
Apr-24-18 01:43PM  Lifshitz & Miller LLP Announces Investigation of Cancer Genetics, Inc., Colony Northstar, Inc., Pacific Commerce Bancorp, MiMedx Group, Inc., Sorrento Therapeutics, Inc., TrueCar, Inc., and Windstream Holdings, Inc. PR Newswire
Apr-23-18 08:00AM  Sorrento Therapeutics CEO Dr. Henry Ji Invited to the Fourth International Vatican Conference on Unite to Cure GlobeNewswire
Apr-16-18 07:01PM  Cramer's lightning round: Take a long-term view on Spotif... CNBC Videos +11.11%
06:50PM  Cramer's lightning round: Take a long-term view on Spotify CNBC
Apr-05-18 02:53PM  Sorrento and Celularity to Start Anti-CD38 CAR-T Phase 1 Clinical Trial in Patients With Relapsed or Refractory Multiple Myeloma (NCT03464916) GlobeNewswire
Apr-04-18 05:46PM  Sorrento Therapeutics to Present at H.C. Wainwright Global Lifesciences Conference 04/09/18 GlobeNewswire +7.84%
Mar-28-18 07:28PM  Sorrento Therapeutics Chairman/CEO update to stockholders GlobeNewswire -26.98%
04:18PM  Why Sorrento Therapeutics Inc. Is Getting Beaten Down Today Motley Fool
Mar-27-18 08:00AM  Sorrento Therapeutics Announces Unsecured $120.5M Convertible Note Financing GlobeNewswire -10.00%
Mar-20-18 11:03PM  Sorrento Therapeutics CEO Dr Ji to Present at Needham 17th Annual Healthcare Conference on 03/27/18 GlobeNewswire +6.62%
Mar-19-18 08:00AM  Sorrento Therapeutics Welcomes Jiong Shao as Chief Financial Officer and Reaffirms Intent to Seek Nasdaq/HKSE Dual Listing in 2018 GlobeNewswire
Mar-14-18 10:08PM  Sorrento Therapeutics to Present at the 28th Annual Oppenheimer Conference (NY) on 03/20/18 GlobeNewswire
05:48PM  Glancy Prongay & Murray LLP Commences Investigation on Behalf of Sorrento Therapeutics, Inc. Investors (SRNE) Business Wire
Mar-08-18 06:16PM  Sorrento Therapeutics CEO Dr. Ji to Present at Roth Capital Partners 30th Annual Growth Stock Conference on 03/12/18 GlobeNewswire
Mar-05-18 08:00AM  Sorrento Therapeutics Autologous Anti-CEA CAR-T Cell Therapy for Liver Metastases Demonstrates Therapeutic Activity in Stage IV Pancreas Cancer in a Phase 1b HITM-SURE Trial (NCT02850536) GlobeNewswire
Mar-01-18 06:53PM  Why an FDA Approval Caused Sorrento Therapeutics' Pain Motley Fool -24.12%
08:20AM  Todays Research Reports on Stocks to Watch: Sorrento Therapeutics and Celgene Corporation ACCESSWIRE
07:19AM  Heres Why Sorrento Is Running Today Market Exclusive
Feb-28-18 03:47PM  FDA approves Sorrento's non-opioid painkiller patch, shares jump Reuters +17.75%
02:16PM  FDA approves Sorrento's painkiller patch Reuters
02:12PM  Sorrento Therapeutics Subsidiary, Scilex, Receives US FDA Approval for Non-Opioid ZTlido (lidocaine topical system) 1.8% for PHN Pain GlobeNewswire
Feb-27-18 01:49PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sorrento Therapeutics, Inc. - SRNE PR Newswire
01:41PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Sorrento Therapeutics, Inc. (SRNE) PR Newswire
Feb-17-18 10:34AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Feb-15-18 01:19PM  Why Sorrento Therapeutics Jumped Higher Today Motley Fool +9.70%
12:00PM  Celularity Announces $250M in Funding to Deliver Treatments for Cancer, Inflammatory and Degenerative Diseases, and Functional Regeneration PR Newswire
Feb-14-18 05:19PM  Does Sorrento Therapeutics Incs (NASDAQ:SRNE) Past Performance Indicate A Stronger Future? Simply Wall St. +13.79%
02:00PM  Biotech Heats Up as Fear of Missing Out Returns TheStreet.com
Feb-08-18 08:20AM  Investor Expectations to Drive Momentum within Mettler-Toledo International, Party City Holdco, Old Dominion Freight Line, Sun Hydraulics, Sorrento Therapeutics, and Lexicon Pharmaceuticals Discovering Underlying Factors of Influence GlobeNewswire
Feb-07-18 08:30AM  Todays Research Reports on Trending Tickers: Argos Therapeutics and Sorrento Therapeutics ACCESSWIRE
Feb-05-18 08:01AM  Sorrento Therapeutics, Inc. Chairman/CEO letter to stockholders GlobeNewswire
08:00AM  Sorrentos and Yuhans Joint Venture, ImmuneOncia, receives Approval to begin clinical trial of Anti-PD-L1 Monoclonal Antibody in South Korea GlobeNewswire
Feb-02-18 08:00AM  Sorrento Therapeutics CEO Dr Ji to Present at LEERINK Partners 7th Global Healthcare Conference on 02/15/18 GlobeNewswire +5.52%
Jan-29-18 08:31AM  BRIEF-Sorrento Says China Oncology Focus Received Approval In China To Begin Clinical Trials For ZKAB001 Reuters
08:06AM  China Oncology Focus Limited Receives Approval by Chinese Authorities to Begin Clinical Trials in Three Separate Cancer Indications Using Sorrentos Anti-PD-L1 Monoclonal Antibody GlobeNewswire
07:15AM  Biotech M&A: Sanofi SA (ADR) Inks 2nd Multi-Billion Dollar Deal in a Week InvestorPlace
Jan-26-18 01:23PM  Building in Biotech, Adding to Twitter TheStreet.com
Jan-24-18 08:00AM  Sorrento Therapeutics CAR-T Manufacturing Capacity Expanded With Opening of East Coast GMP Site in Addition to Primary West Coast Facility GlobeNewswire
Jan-23-18 08:10AM  Todays Research Reports on Stocks to Watch: Array BioPharma and Sorrento Therapeutics ACCESSWIRE
Jan-22-18 12:21PM  Why Sorrento Therapeutics Inc Jumped Higher Today Motley Fool +21.09%
08:00AM  Sorrento Therapeutics to Present at Noble Capital Markets Fourteenth Annual Investor Conference on 01/29/18 GlobeNewswire
Jan-20-18 10:34AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jan-06-18 10:34AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jan-02-18 08:00AM  Sorrento Therapeutics to Present Potential Game-Changer Non-Viral CAR-T Technology for Autologous and Allogeneic (off-the-shelf) CAR-T Therapies GlobeNewswire +22.37%
Jan-01-18 09:18AM  Sorrento Therapeutics, Inc. :SRNE-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018 Capital Cube
Dec-27-17 11:51AM  ETFs with exposure to Sorrento Therapeutics, Inc. : December 27, 2017 Capital Cube -7.97%
Nov-17-17 12:58PM  ETFs with exposure to Sorrento Therapeutics, Inc. : November 17, 2017 Capital Cube
08:30AM  New Research Coverage Highlights Principal Financial Group, Dunkin' Brands Group, Dell Technologies, Paramount Group, Sorrento Therapeutics, and Lexicon Pharmaceuticals Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Nov-14-17 09:00AM  Scilex Pharmaceuticals, Sorrento Therapeutics' Subsidiary, Files Marketing Authorization Application In The European Union For ZTlido PR Newswire -8.00%
Nov-02-17 12:35PM  ETFs with exposure to Sorrento Therapeutics, Inc. : November 2, 2017 Capital Cube
Oct-25-17 08:00AM  Adgero Biopharmaceuticals Appoints John Liatos as Chief Financial Officer Marketwired
Oct-23-17 11:06AM  ETFs with exposure to Sorrento Therapeutics, Inc. : October 23, 2017 Capital Cube -7.14%
Oct-14-17 10:34AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Oct-10-17 11:50AM  ETFs with exposure to Sorrento Therapeutics, Inc. : October 10, 2017 Capital Cube +19.05%
08:10AM  Today's Research Reports on Stocks to Watch: Onconova Therapeutics and Sorrento Therapeutics ACCESSWIRE
Oct-05-17 02:37PM  H.C. Wainwright Sees Over 1000% Upside for Sorrento Therapeutics (SRNE) Investopedia
Oct-02-17 08:00AM  Sorrento Therapeutics Appoints Mr. Dorman Followwill And Mr. Dave Lemus To The Board Of Directors PR Newswire
Sep-19-17 08:00AM  Sorrento Therapeutics, Inc. To Present At Cantor Global Healthcare Conference (09/25/17 - 2:25 PM ET) PR Newswire -5.41%
Sep-12-17 06:00AM  FDA Acknowledges Receipt Of Sorrento Therapeutics Inc, NDA For ZTlido; PDUFA Date Set For February 28, 2018 PR Newswire
Sep-08-17 04:03PM  Sorrento Therapeutics, Inc. To Present At 19th Rodman And Renshaw Global Investment Conference (09/11/17 - 17:30 ET) PR Newswire
Aug-31-17 09:09PM  ETFs with exposure to Sorrento Therapeutics, Inc. : September 1, 2017 Capital Cube
07:10AM  Featured Company News - Sorrento Submits NDA for ZTlido Next-Gen Lidocaine Patch; Intends to File an MAA in Europe ACCESSWIRE
Aug-29-17 06:00AM  Sorrento Therapeutics, Inc. Submits NDA For ZTlido Next-Generation Lidocaine Patch PR Newswire -7.14%
Aug-25-17 12:29PM  Sorrento Therapeutics, Inc. :SRNE-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017 Capital Cube
Aug-21-17 05:21PM  Sorrento Contributes To The Formation Of Celularity, Inc. For Breakthrough Placental Therapeutic Platform In Consortium With Leading Pharmaceutical Companies PR Newswire
04:48PM  Celularity, Inc., Accelerates Breakthrough Placental Discovery & Therapeutic Platform PR Newswire
04:22PM  Celularity, Inc., Accelerates Breakthrough Placental Discovery & Therapeutic Platform CNW Group
Jul-17-17 08:50AM  Today's Research Reports on Stocks to Watch: Sorrento Therapeutics and Omeros Corporation Accesswire
Jun-30-17 03:24PM  ETFs with exposure to Sorrento Therapeutics, Inc. : June 30, 2017 Capital Cube
Jun-29-17 12:22PM  Sorrento Therapeutics Announced FDA Authorization of IND to Commence Clinical Trial of RTX in Intractable Cancer Pain PR Newswire
Jun-26-17 07:00AM  Semnur Pharmaceuticals, Inc., Announces Successful Phase 1 / 2 Trial in Patients with Radicular Pain for Its Lead Product, SP-102 PR Newswire +13.51%
Jun-16-17 04:21PM  ETFs with exposure to Sorrento Therapeutics, Inc. : June 16, 2017 Capital Cube +8.11%
Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. The company is focusing on the development of chimeric antigen receptor (CAR)-based immunotherapies using autologous T-cells. It is developing CD38 Directed CAR-T, a cellular therapy used for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases; CD123 Directed CAR-T for the treatment of acute myelogenous leukemia; and human antibodies, including PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, CCR2, OX40, TIGIT, and CD137. The company is also developing intracellular targeting antibodies comprising STAT3, Mutant KRAS, MYC, p53, and TAU to modulate the evolution of cancer, inflammation, autoimmune diseases, diabetes, central nervous system diseases, cardiovascular diseases, and viral infections; and oncolytic viruses that infect and selectively multiply in and destroy tumor cells without damaging healthy tissue. In addition, it offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. The company has a licensing agreement with Mabtech Limited to develop and commercialize multiple prespecified biosimilar and biobetter antibodies from based on Erbitux, Remicade, Xolair, and Simulect. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ABG Management Ltd10% OwnerSep 13Sale4.94107,814532,6251,013,020Sep 14 04:12 PM
ABG Management Ltd10% OwnerSep 12Sale5.06189,754960,0981,120,834Sep 14 04:12 PM
Ji HenrySee RemarksJul 20Option Exercise1.756,00010,5002,045,807Jul 23 06:50 AM
Ji HenrySee RemarksFeb 28Buy9.9564,600642,7701,906,177Feb 28 07:04 PM
Ng George KSee RemarksFeb 28Buy9.9590,000895,500101,453Feb 28 07:04 PM
ABG Management Ltd10% OwnerFeb 07Sale7.19150,0001,077,9751,328,529Feb 08 08:17 AM
ABG Management Ltd10% OwnerFeb 06Sale6.75512,9123,464,2591,478,529Feb 08 08:17 AM
ABG Management Ltd10% OwnerFeb 05Sale8.0070,721566,0371,310,588Feb 07 08:35 AM
ABG Management Ltd10% OwnerJan 30Sale7.65235,1561,799,5781,326,853Jan 31 09:09 AM
ABG Management Ltd10% OwnerJan 29Sale7.6174,844569,2861,380,639Jan 31 09:09 AM
Asia Pacific MedTech (BVI) Ltd10% OwnerJan 24Sale7.52577,9624,343,7318,617,513Jan 25 04:57 PM
Asia Pacific MedTech (BVI) Ltd10% OwnerJan 23Sale7.82106,326831,9589,195,475Jan 25 04:57 PM